New perspectives on management of idiopathic pulmonary fibrosis

Therapeutic Advances in Chronic Disease

Volumn 7, Issue 2, 2016, Pages 108-120

  Puglisi, Silvia ^a   Torrisi, Sebastiano Emanuele ^a   Vindigni, Virginia ^a   Giuliano, Riccardo ^a   Palmucci, Stefano ^b   Mulè, Massimiliano ^c   Vancheri, Carlo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

exacerbation; management; nintedanib; pirfenidone; pulmonary fibrosis

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; GAMMA1B INTERFERON; INTERLEUKIN 13; NINTEDANIB; PIRFENIDONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

BRONCHIECTASIS; CANCER RISK; CLINICAL TRIAL (TOPIC); COMORBIDITY; DISEASE COURSE; DISEASE EXACERBATION; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROESOPHAGEAL REFLUX; LUNG CANCER; LUNG TRANSPLANTATION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDERED BREATHING;

EID: 84959321189     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315624276     Document Type: Review

References (85)

1. A.AgustiR.Rodriguez-Roisin (1993) Effect of pulmonary hypertension on gas exchange. Eur Respir J6: 1371–1377.
2. Y.AonoY.NishiokaM.InayamaM.UgaiJ.KishiH.Uehara. (2005) Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med171: 1279–1285.
3. S.ArcasoyJ.ChristieV.FerrariM.SuttonD.ZismanN.Blumenthal. (2003) Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med167: 735–740.
4. M.AubryJ.MyersW.DouglasH.TazelaarT.Washington StephensT.Hartman. (2002) Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc77: 763–770.
5. A.AzumaT.NukiwaE.TsuboiM.SugaS.AbeK.Nakata. (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med171: 1040–1047.
6. V.Barry-HamiltonR.SanglerD.MarshallS.McCauleyH.RodriguezM.Oyasu. (2010) Allosteric inhibition of lixil oxidase like 2 impedes the development of a pathologic microenvironment. Nat Med16: 1009–1017.
7. G.BispingM.KropffD.WenningB.DreyerS.BessonovF.Hilberg. (2005) Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6secretion and induction of apoptosis in cytogenetically defined subgroups. Blood107: 2079–2089.
8. A.BoutouG.PitsiouI.TrigonisD.PapakostaP.KontouN.Chavouzis. (2011) Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension. Respirology16: 451–458.
9. B.BradleyH.BranleyJ.EganM.GreavesD.HansellN.Harrison. (2008) Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax63(Suppl. 5): v1–v58.
10. N.ChaudharyG.RothF.HilbergJ.Muller-QuernheimA.PrasseG.Zissel. (2007) Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J29: 976–985.
11. U.CostabelE.BendstrupV.CottinP.DewintJ.EganJ.Ferguson. (2014) Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther31: 375–391.
12. C.DanielsJ.LaskyA.LimperK.MierasE.GaborD.Schroeder. (2010) Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebocontrolled trial results. Am J Respir Crit Care Med181: 604–610.
13. N.HamadaK.KuwanoM.YamadaN.HagimotoK.HiasaK.Egashira. (2005) Antivascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol175: 1224–1231.
14. K.HamadaS.NagaiS.TanakaT.HandaM.ShigematsuT.Nagao. (2007) Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest131: 650–656.
15. F.HilbergG.RothM.KrssakS.KautschitschW.SommergruberU.Tontsch-Grunt. (2008) BIBF1120: triple angiokinase inhibitor with sustained receptor blockade and good anti tumor efficacy. Cancer Res68: 4774–4782.
16. Y.InoueT.KingJrE.BarkerE.DaniloffL.Newman (2002) Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med166: 765–773.
17. D.JastrzebskiA.GumolaR.GawlikJ.Kozielski (2006) Dyspnea and quality of life in patients with pulmonary fibrosis after six weeks of respiratory rehabilitation. J Physiol Pharmacol57(Suppl. 4): 139–148.
18. E.JudgeA.FabreH.AdamaliJ.Egan (2012) Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J40: 93–100.
19. T.KingJrC.AlberaW.BradfordU.CostabelP.HormelL.Lancaster. (2009) Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet374: 222–228.
20. T.KingJrJ.BehrK.BrownR.du BoisL.LancasterJ.de Andrade. (2008) BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med177: 75–81.
21. T.KingJrW.BradfordS.Castro-BernardiniE.FaganI.GlaspoleM.Glassberg. (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med370: 2083–2092.
22. T.KingJ.ToozeM.SchwarzK.BrownR.Cherniack (2001) Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med164: 1171–1181.
23. K.KishiS.HommaA.KurosakiN.MotoiK.Yoshimura (2006) High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr30: 95–99.
24. L.KolilekasE.ManaliK.VlamiP.LyberopoulosC.TriantafillidouK.Kagouridis. (2013) Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med9: 593–601.
25. Y.KondohH.TaniguchiM.KitaichiT.YokoiT.JohkohT.Oishi. (2006) Acute exacerbation of interstitial pneumonia following surgical lung biopsy. Respir Med100: 1753–1759.
26. V.KrishnanM.McCormackS.MathaiS.AgarwalB.RichardsonM.Horton. (2008) Sleep quality and health-related quality of life in idiopathic pulmonary fibrosis. Chest134: 693–698.
27. H.KuboK.NakayamaM.YanaiT.SuzukiM.YamayaM.Watanabe. (2005) Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest128: 1475–1482.
28. P.KumarP.GoldstrawK.YamadaA.NicholsonA.Wells (2013) Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg125: 1321–1327.
29. L.LancasterW.MasonJ.ParnellT.RiceJ.LoydA.Milstone. (2009) Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest136: 772–778.
30. D.LedererS.JelicR.BasnerJ.Bhattacharya (2012) Is obstructive sleep apnea a cause ofidiopathic pulmonary fibrosis?Arch Pathol Lab Med136: 470.
31. J.LeeH.CollardK.AnstromF.MartinezI.NothR.Roberts. (2013) Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials. Lancet Respir Med1: 369–376.
32. A.LeeI.Mira-AvendanoJ.RyuC.Daniels (2014a) The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med108: 955–967.
33. T.LeeJ.ParkH.LeeY.ChoH.YoonJ.Lee. (2014b) Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med108: 1549–1555.
34. I.Le JeuneJ.GribbinJ.WestC.SmithP.CullinanR.Hubbard (2007) The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med101: 2534–2540.
35. C.LettieriS.NathanS.BarnettS.AhmadA.Shorr (2006) Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest129: 746–752.
36. M.LiS.MathurN.ChowdhuryD.HelmL.Singer (2013) Pulmonary rehabilitation in lung transplant candidates. J Heart Lung Transplant32: 626–632.
37. F.MartinezS.SafrinD.WeyckerK.StarkoW.BradfordT.KingJr. (2005) The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med142: 963–967.
38. J.McCartneyK.Meyer (2008) Optimizing post-transplant outcomes in lung transplantation. Expert Rev Respir Med2:183–199.
39. C.MermigkisI.BouloukakiK.AntoniouG.PapadogiannisI.GiannarakisG.Varouchakis. (2015) Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath19: 385–391.
40. O.A.MinaiJ.F.SantacruzJ.M.AlsterM.M.BudevK.McCarthy (2012) Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med106: 1613–1621.
41. E.MorawiecI.Tillie-LeblondV.PansiniJ.SalleronM.Remy-JardinB.Wallaert (2011) Exacerbations of idiopathic pulmonary fibrosis treated with corticosteroids and cyclophosphamide pulses. Eur Respir J38: 1487–1489.
42. R.Morehead (2009) Gastro-oesophageal reflux disease and non-asthma lung disease. Eur Respir Rev18: 233–243.
43. L.MurrayR.ArgentieriF.FarrelM.BrachtH.ShengB.Whitaker. (2008) Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGF beta1, IL13 and CCl2. Int J Biochem Cell Biol40: 2174–2182.
44. H.NadrousP.PellikkaM.KrowkaK.SwansonN.ChaowalitP.Decker. (2005) Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest128: 2393–2399.
45. T.NakamuraY.KawagoeT.MatsudaH.ShojiY.UedaN.Tamura. (2004) Effect of polymyxin B-immobilized fiber on blood metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in acute respiratory distress syndrome patients. Blood Purif22: 256–260.
46. S.NakayamaH.MukaeN.SakamotoT.KakugawaS.YoshiokaH.Soda. (2008) Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci82: 210–217.
47. V.NavaratnamK.M.FlemingJ.WestC.J.SmithR.G.JenkinsA.FogartyR.B.Hubbard (2011) The rising incidence of idiopathic pulmonary fibrosis in the U.K.Thorax66(6): 462–467.
48. O.NishiyamaY.KondohT.KimuraK.KatoK.KataokaT.Ogawa. (2008) Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology13: 394–399.
49. P.NobleC.AlberaW.BradfordU.CostabelM.GlassbergD.Kardatzke. (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet377: 1760–1769.
50. I.NothK.AnstromB.CalvertJ.de AndradeK.FlahertyC.Glazer. (2012) A placebocontrolled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med186: 88–95.
51. A.OlsonJ.SwigrisD.LezotteJ.NorrisC.WilsonK.Brown (2007) Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med176: 277–284.
52. Y.OzawaT.SudaT.NaitoN.EnomotoD.HashimotoT.Fujisawa. (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology14: 723–728.
53. J.ParkD.S.KimT.S.ShimC.M.LimY.KohS.D.Lee. (2001) Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J17(6): 1216–1219.
54. G.RaghuK.AnstromT.King (2012) Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med366: 1968–1977.
55. G.RaghuJ.BehrK.BrownJ.EganS.KawutK.Flaherty. (2013) Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med158: 641–649.
56. G.RaghuK.BrownU.CostabelV.CottinR.du BoisJ.Lasky. (2008) Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med178: 948–955.
57. G.RaghuH.CollardJ.EganF.MartinezJ.BehrK.Brown. (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med183: 788–824.
58. G.RaghuT.FreudenbergerS.YangJ.CurtisC.SpadaJ.Hayes. (2006a) High prevalence of abnormal acid reflux in idiopathic pulmonary fibrosis. Eur Respir J27: 136–142.
59. G.RaghuB.RochwergY.ZhangC.Cuello GarciaA.AzumaJ.Behr. (2015) An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med192: e3–e19.
60. G.RaghuD.WeyckerJ.EdelsbergW.BradfordG.Oster (2006b) Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med174: 810–816.
61. G.RaghuS.YangC.SpadaJ.HayesC.Pellegrini (2006c) Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest129: 794–800.
62. K.RascheM.Orth (2009) Sleep and breathing in idiopathic pulmonary fibrosis. J Physiol Pharmacol60(Suppl. 5): 13–14.
63. L.RicheldiU.CostabelM.SelmanD.KimD.HansellA.Nicholson. (2011) Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med365: 1079–1087.
64. L.RicheldiH.DaviesG.FerraraF.Franco (2003) Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev3: CD002880.
65. L.RicheldiR.du BoisG.RaghuA.AzumaK.BrownU.Costabel. (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med370: 2071–2082.
66. S.SakamotoS.HommaM.MunT.FujiiA.KurosakiK.Yoshimura (2011) Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study. Intern Med50: 77–85.
67. B.SalhiT.TroostersM.BehaegelG.JoosE.De-rom (2010) Effects of pulmonary rehabilitation in patients with restrictive lung diseases. Chest137: 273–279.
68. L.SchachterJ.DixonR.PierceP.O’Brien (2003) Severe gastroesophageal reflux is associated with reduced carbon monoxide diffusing capacity. Chest123: 1932–1938.
69. W.SeegerS.Pullamsetti (2013) Mechanics and mechanisms of pulmonary hypertension-Conference summary and translational perspectives. Pulm Circ3: 128–136.
70. W.SeegerY.AdirJ.A.BarberàH.ChampionJ.G.CoghlanV.Cottin. (2013) Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol62(25Suppl): D109-D116.
71. A.ShorrJ.WainrightC.CorsC.LettieriS.Nathan (2007) Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J30: 715–721.
72. G.SimonneauM.GatzoulisI.AdatiaD.CelermajerC.DentonA.Ghofrani. (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol62(Suppl. 25): D34–D41.
73. J.SongS.HongC.LimY.KohD.Kim (2011) Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J37: 356–363.
74. P.SpagnoloC.Del GiovaneF.LuppiS.CerriS.BalduzziE.Walters. (2010) Non steroid agents for idiopathic pulmonary fibrosis. Eur Respir J35: 821–829.
75. J.SwigrisK.BrownJ.BehrR.duBoisT.KingG.Raghu. (2010) The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med104: 296–304.
76. T.TakadaK.AsakawaT.SakagamiH.MoriyamaJ.KazamaE.Suzuki. (2014) Effects of direct hemoperfusion with polymyxin B-immobilized fiber on rapidly progressive interstitial lung diseases. Intern Med53: 1921–1926.
77. H.TaniguchiM.EbinaY.KondohT.OguraA.AzumaM.Suga. (2010) Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J35: 821–829.
78. S.TomassettiC.GurioliJ.RyuP.DeckerC.RavagliaP.Tantalocco. (2015) The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest147: 157–164.
79. L.TroyT.Corte (2014) Sleep disordered breathing in interstitial lung disease: a review. World J Clin Cases2: 828–834.
80. A.WatanabeT.HigamiS.OhoriT.KoyanagiS.NakashimaT.Mawatari (2008) Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?J Thorac Cardiovasc Surg136: 1357–1363.
81. W.WuytsK.AntoniouK.BorensztajnU.CostabelV.CottinB.Crestani. (2014) Combination therapy: the future of management for idiopathic pulmonary fibrosis?Lancet Respir Med2: 933–942.
82. M.WygreckaG.KwapiszewskaE.JablonskaS.von GerlachI.HennekeD.Zakrzewicz. (2011) Role of protease-activated receptor 2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med183: 1703–1714.
83. T.YoungM.PaltaJ.DempseyP.PeppardF.NietoK.Hla (2009) Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ108: 246–249.
84. Y.ZhuoJ.ZhangM.LaboyJ.Lasky (2004) Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol286: L182–L188.
85. D.ZismanM.SchwarzK.AnstromH.CollardK.FlahertyG.Hunninghake. (2010) A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med363: 620–628.